In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications ... The strong ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.

The role of RNA in a function called RNA interference — where small RNA molecules keep a gene from being expressed — has been ...

This analysis is crucial because it will help validate our AI driven hypothesis that has been validated in vitro and in vivo and also through CRISPR experimentation, but now we can also validate it in ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use ... The strong preclinical data for HG202, combined with promising results from the first-in-human ‘SIGHT-I’ trial ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Even treated with the most advanced therapies, patients with glioblastoma—an aggressive brain cancer—typically survive less ...

In a cell-based study, researchers have forced glioblastoma cells to display immune system targets, making them visible to ...

Researchers have identified a possible way to make glioblastoma cells vulnerable to different types of immunotherapy. The strategy, which they demonstrated in cells in the lab, forces brain cancer ...